Keisuke Motoyama

Keisuke Motoyama

Auto-generated profile, based on publicly available information

Keisuke Motoyama

Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KMKeisuke Motoyama
Keisuke Motoyama
TNTsutomu Nagata
Tsutomu Nagata
JKJun Kobayashi
Jun Kobayashi
ANAkifumi Nakamura
Akifumi Nakamura
NMNaoki Miyoshi
Naoki Miyoshi
TSTomoko Sakakura
Tomoko Sakakura

10 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SAShandon M. Amos
Shandon M. Amos
CCChi-Chao Chen
Chi-Chao Chen
YXYichen Xiang
Yichen Xiang
KMKeisuke Motoyama
Keisuke Motoyama
TGTania J. González-Robles
Tania J. González-Robles
YSYadira M. Soto-Feliciano
Yadira M. Soto-Feliciano
Chromatin regulation critically influences gene expression and cancer progression, yet the functions of chromatin adaptors remain incompletely defined. Using focused CRISPR screening, we identified TRIM28, a multi-domain chromatin adaptor, as a dependency in acute leukemia, where its depletion impaired leukemia cell proliferation in vitro and in vivo , while activating neutrophil differentiation programs. Integrative transcriptomic and chromatin profiling revealed that TRIM28 acts as a co-repressor of neutrophil-associated loci independently of H3K9 methylation, and that TRIM28 loss drives terminal differentiation of leukemia cells into functionally mature neutrophil-like cells with reduced leukemic potential. We developed a selective small-molecule TRIM28 inhibitor that binds the TRIM28 PHD-bromodomain, phenocopies TRIM28 loss across biochemical and cellular assays, exhibits low micromolar anti-leukemia activity, induces neutrophil differentiation, and synergizes with Menin inhibition. Together, these findings, spanning target discovery, mechanism of action, and chemical probe development, establish TRIM28 as a regulator of myeloid cell fate and a promising pro-differentiation therapeutic target in acute leukemia.